Fact based stock research
Carl Zeiss Meditec (XTRA:AFX)


Carl Zeiss Meditec stock research in summary

tec.zeiss.com


Carl Zeiss Meditec shares have a HOLD rating. While they show above average growth, they are riskily financed, and are bad value. We recommend holding Carl Zeiss Meditec shares.


Latest Obermatt Ranks


Country Germany
Industry Health Care Equipment
Index TecDAX, CDAX
Size class Medium

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock



Research History: Carl Zeiss Meditec

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
97
39
28
32
STOCK GROWTH RANKS
23
11
63
65
STOCK SAFETY RANKS
55
87
58
42
COMBINED STOCK RANKS
73
44
47
52

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Carl Zeiss Meditec in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Carl Zeiss Meditec; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
6
3
50
48
PROFIT GROWTH
77
77
77
56
STOCK RETURNS
61
79
87
80
CONSOLIDATED RANK: GROWTH
23
11
63
65

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Carl Zeiss Meditec.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
13
46
50
43
REFINANCING
68
62
65
62
LIQUIDITY
65
96
68
54
CONSOLIDATED RANK: SAFETY
55
87
58
42

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Carl Zeiss Meditec and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Carl Zeiss Meditec from June 8, 2018.